For the second time in the space of a month AstraZeneca has stopped a trial of its chronic lymphocytic leukaemia (CLL) drug Calquence (acalabrutinib) early following positive results.
AstraZeneca has said that it will stop a Phase III trial of its chronic lymphocytic leukaemia drug Calquence (acalabrutinib) early after the drug met its primary endpoint in an interim anal
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.